At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform Radiation Therapy Decisions In Older Women With Early-Stage Breast Cancer
In Brief
A Phase 2 clinical trial evaluating tamoxifen, letrozole, anastrozole, or exemestane and Patient reported outcomes for Breast Cancer Female. Active but no longer recruiting, targeting 84 participants across 2 sites.
Detailed Summary
This is a prospective multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated with 3 months of pre-operative endocrine therapy (pre-ET) with assessment of tolerance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).
Study Details
Timeline
Interventions
choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
Questionnaire inquiries include the following: * how cancer affects daily living * beliefs about medicines and sensitivity to medicine * symptoms * adherence to endocrine therapy * general health and well being * depression and anxiety * preference regarding radiation therapy